Genome-wide association studies (GWAS) have identified more than 100 schizophrenia (SCZ)-associated loci, but using these findings to illuminate disease biology remains a challenge. Here we present integrative risk gene selector (iRIGS), a Bayesian framework that integrates multi-omics data and gene networks to infer risk genes in GWAS loci. By applying iRIGS to SCZ GWAS data, we predicted a set of high-confidence risk genes, most of which are not the nearest genes to the GWAS index variants. High-confidence risk genes account for a significantly enriched heritability, as estimated by stratified linkage disequilibrium score regression. Moreover, high-confidence risk genes are predominantly expressed in brain tissues, especially prenatally, and are enriched for targets of approved drugs, suggesting opportunities to reposition existing drugs for SCZ. Thus, iRIGS can leverage accumulating functional genomics and GWAS data to advance our understanding of SCZ etiology and potential therapeutics.
F
or most complex diseases, translating GWAS findings to uncover their underlying biological mechanisms and clinical applicability remains a great challenge 1 . While drug development guided by genetic evidence should have greater rates of success 2 , few effective drug targets have been identified through GWAS analysis thus far. SCZ represents a paradigmatic example of this challenge. The Psychiatric Genomics Consortium has assembled tens of thousands of samples worldwide and reported 108 genomic loci associated with SCZ in a milestone paper 3 . However, only one recognized drug target, the dopamine receptor D2 (encoded by DRD2), stood out from the results. The therapeutic impasse is largely a consequence of the paucity of novel targetable genes that can be accurately manipulated with drugs 4 . For most, if not all, GWAS loci it is non-trivial to pinpoint the corresponding risk genes, as the loci usually cover multiple candidate genes and the genuine risk gene (or genes) may be megabases away from the index single nucleotide polymorphisms (SNPs) 5 . Genes closest to index SNPs were intuitively assigned as risk genes in previous studies 6 ; however, there is increasing evidence to suggest that risk genes may not be those in closest proximity to index SNPs 7 .
There has been tremendous effort in the past few years to dissect the machinery of gene regulation. Epigenomics data generated in large-scale projects such as Functional Annotation of the Mammalian Genome 5 (FANTOM5) provide critical links between regulatory elements and the genes that they regulate 8 . Moreover, the recent advances of genome-scale chromosome conformation capture (Hi-C) technology provide global views of both short-and long-range interactions among genomic loci 9, 10 . Hi-C data have been successfully used to infer the long-range interaction between distal regulatory elements (DREs) and target promoters 9, 10 . These studies showed the promise of linking GWAS loci to disease risk genes; however, such data accumulated to date are far from satisfactory. Meanwhile, individual omics data provide complementary support so that integrating multi-omics data is expected to strengthen the signal for pinpointing risk genes. At a different level, multi-omics data on individual risk genes are further amplified when multiple risk genes are considered together, particularly given the polygenicity of diseases such as SCZ and that disease risk genes often converge on related biological processes. Intuitively, the increased precision achieved by using the joint modeling approach is due to borrowing supporting evidence from risk genes across all GWAS loci.
In this study, we developed a Bayesian framework, entitled iRIGS, to probabilistically infer risk genes driving GWAS signals by integrating the following two layers of information: (1) multiple lines of supporting evidence from multi-omics data for individual genes, and (2) relationships of genes in the biological networks. In its simplest form, the framework can be viewed as a Bayesian model selection problem; that is, to select genes from each of the GWAS loci such that the supporting evidence on the selected risk genes from all loci is collectively high. The proposed method is flexible in that it can leverage data from different sources (for example, transcriptomics and epigenomics data) and cumulatively orchestrate them to calculate the probability for risk gene prediction. The application of iRIGS to SCZ showed that our predicted risk genes explain significantly enriched heritability, are highly consistent with the leading pathophysiological hypotheses of SCZ, and are significantly enriched in targets of approved drugs. Taken together, these results confirm and greatly expand our previous understanding of the disease biology of SCZ and support the ability of our framework in translating GWAS findings into biological mechanisms and clinical applicability.
Results
Overview of the iRIGS framework. Figure 1 provides a schematic of the framework. Let L denote the number of GWAS loci, and for a specific locus we collected all the genes located within a 2 Mb region centered at the index SNP as its candidates. The goal of iRIGS is to probabilistically rank candidate genes at each GWAS locus based on their cumulative supporting evidence and closeness in a gene-gene network. Specifically, our goal is to find a set of L genes, each selected from one GWAS locus, such that the selected L genes achieve the highest score underlying a specified scoring scheme. Computationally, it is infeasible to enumerate all possible gene combinations; therefore, we adopted a Gibbs sampling algorithm to address the challenge, transitioning the problem into a conditional single-dimensional sampling procedure. For example, when sampling the risk gene from candidates at the L-th locus, we assume that the risk genes at all other (L -1) loci have been selected, and the sampling probability for a gene at the L-th locus is computed conditionally on the (L -1) risk genes based on the combined supporting evidence from this gene's multi-omics data as well as its closeness to the other (L -1) risk genes in the network. The sampled Candidate genes from different GWAS loci are stacked vertically. In the middle of the figure, the risk genes for the (L -1) loci have already been sampled, and for the L-th locus, the colors of the genes represent the strength of the support from genomic features as well as the closeness to the (L -1) sampled risk genes in the network space. After the sampling converges, the candidate gene with the highest PP at each locus is denoted as the inferred risk gene.
gene at the L-th locus is then put back into the set of selected genes, and the sampling for the (L -1)-th locus is iterated until all the loci are visited. This process is repeated until risk genes converge on a stationary distribution. The posterior probability (PP) of each candidate being a risk gene can be assessed on the basis of the sampling frequency. For each GWAS locus, one or potentially more risk genes can be selected according to the PP. In this study, we only selected one risk gene with the highest PP for each locus. Details of iRIGS can be found in the Methods and the Supplementary Note.
Applying iRIGS to identify disease risk genes for SCZ. In a milestone paper of a GWAS of SCZ, the Psychiatric Genomics Consortium reported 108 independent, genome wide-significant loci 3 . We performed iRIGS on these loci to identify risk genes for SCZ (Supplementary Table 1) . A key component of iRIGS is a collection of genomic features that can be used to characterize SCZ risk genes. Given our limited knowledge of the disease genes of SCZ, genuine characterization of genomic features of SCZ risk genes has not been clearly established. Here, we adapted iRIGS in a special form to infer preliminary SCZ risk genes to carry out an ab initio discovery of associated genomic features. Specifically, we used a generic gene-gene network constructed from Gene Ontology (GO) to run iRIGS without genomics data (Methods), and denoted the identified risk genes as network-derived risk genes (NRGs). In total, we predicted 104 NRGs after merging the overlapping genes across loci.
To show that these 104 NRGs harbor genuine SCZ risk genes, we assessed the enrichment of NRGs with 18 gene sets that have been widely and repeatedly implicated in SCZ (Methods). For the enrichment analysis, we selected the 842 genes with PP values less than the median PP of all candidate genes as the background and termed them local background genes (LBGs). We observed significant enrichments in five gene sets after Bonferroni correction (Table 1) , odds ratio (OR) = 4.52) and microRNA-137 (miR-137) targets (P corrected = 4.24 × 10 −5 , OR = 9.79). We also tried other thresholds to define LBGs, and found that the enrichment patterns were similar (Supplementary Table 2 ). Thus, in subsequent analyses, we used the median PP as the LBG threshold. To further determine that the enrichment is not biased owing to GO annotations, we applied iRIGS to two other traits (age-related macular degeneration and obesity) using the same GO network. No enrichments were observed in any of these gene sets (P corrected > 0.05).
We also evaluated whether NRGs carry more de novo mutations (DNMs) identified in SCZ compared to LBGs. We collected DNM data of parent-proband trios as well as unaffected siblings from previous studies 11 (Methods). We only focused on the predicted deleterious DNMs (pdDNMs), defined as loss-of-function (nonsense, splicing, and frame shift) DNMs or missense DNMs with a deleterious score (DScore) of >3, in which DScore is defined as the number of deleteriousness predictions among 12 algorithms reported by ANNOVAR 12 (Methods). We observed a significant enrichment of proband pdDNMs with NRGs (P = 2.53 × 10 −3 , OR = 3.88), while no enrichment was observed for synonymous DNMs (P = 1). By contrast, no significant enrichments were observed for either pdDNMs (P = 1) or synonymous DNMs (P = 1) identified in unaffected siblings.
Discovery of characteristic genomic features of SCZ risk genes.
These preliminary explorations showed that the predicted NRGs capture the genetic risks of SCZ. We therefore used the 104 NRGs to explore genomics data and to learn genomic features that are characteristics of SCZ risk genes. First, we found that NRGs are more likely to exhibit differential expression (DE) compared to LBGs (P = 8.55 × 10 −3 ) (Fig. 2a) in the CommondMind data 13 (Methods). We next explored DRE-promoter links of NRGs by testing the hypothesis that risk genes have more incoming regulatory links compared to background levels. We found that NRGs are indeed connected to more DREs in the Hi-C and FANTOM5 data (Fig. 2b,  Supplementary Fig. 1 , Methods, and Supplementary Note). We also , this will nevertheless be the case for a number of risk loci. Among the 104 NRGs we predicted, 23 genes (22%) were the nearest ones to the corresponding index SNPs, significantly higher than expected (P = 0.04, permutation test).
Integrating the learned genomic features to identify high-confidence risk genes for SCZ. As shown above, different genomic features (that is, DNMs, DE, DRE-promoter links, and distance to index SNP (DTS)) consistently exhibited supportive evidence for NRGs. We therefore integrated them into iRIGS (Methods) and predicted a total of 104 high-confidence risk genes (HRGs) (Supplementary Table 1 ). We next evaluated whether and how the integrated multidimensional genomic features can improve our prediction.
Genomic features show aggregated effects on HRGs.
For each GWAS locus, we calculated the ratio of maximum and median PP values of local candidate genes and found that HRGs carry significantly higher sampling probabilities than NRGs (P = 1.02 × 10
) (Fig.  3a) . This result demonstrates the strong and aggregated influence of multidimensional genomic features on nominating risk genes.
Genomic positions of HRGs relative to GWAS index SNPs.
Among the 104 HRGs, 39 genes (38%) were nearest to the corresponding GWAS index SNPs (16 more genes than NRGs), significantly higher than expected (P < 1 × 10
, permutation test). The extreme significance strongly supports the effectiveness of incorporating genomic features in selecting genuine risk genes. In particular, HRGs that are also the nearest genes to index SNPs provide high-confidence candidates for follow-up studies.
Of particular interest are the remaining 65 HRGs that are not the nearest genes to the index SNPs. For each of these 65 HRGs, denoted as non-nearest HRGs, we picked the nearest gene from the corresponding locus as a control. We also performed a gene set enrichment analysis to compare the 65 nearest non-HRG genes with the 65 non-nearest HRGs. The gene sets used here for this analysis are the same as the ones presented in Table 1 . We found that the non-nearest HRGs are more significantly enriched in the gene sets compared to the nearest non-HRG genes (Supplementary Table 3 ), suggesting that the 65 non-nearest HRGs identified by iRIGS are more likely to be true risk genes than their nearest counterparts.
In the 2 Mbp window of GWAS index SNPs, most candidate genes were out of the linkage disequilibrium (LD) blocks of the index SNPs. We therefore investigated the extent to which the identified HRGs are in GWAS loci LD blocks, which were defined as regions with r 2 > 0.2 with the index SNPs. Among the 104 identified HRGs, 34 (33%) genes were in LD blocks. For 39 HRGs that were also nearest to the index SNPs, around half (19) were in LD blocks, while for the 65 non-nearest HRGs, only 15 were in LD blocks.
HRGs explain high disease heritability. We then utilized stratified LD score regression (LDSC) to evaluate the SCZ heritability explained by HRGs 14 . We included the SNPs located within a 20 kb window centered at the transcription start site of each gene for LDSC analysis. We observed that HRGs explain significantly enriched disease heritability (enrichment = 39.36, P = 5.56 × 10 ) (Fig. 3b) . When only focusing on the 65 non-nearest HRGs, we also observed a significant enrichment in heritability (enrichment = 19.72, P = 2.53 × 10 −4 ); however, the majority of these were not in strong LD with the index SNPs (Fig. 3b) . As expected, the enrichment of nearest HRGs was the highest, since they are close to index SNPs. We also tried different window sizes around the transcription start site (from 20 kb to 200 kb) for LDSC and observed the same trend of enrichments. Note that DTS is a confounding effect for LDSC, since genes close to index SNPs are more likely to have a high LDSC score, and the HRGs used here for the LDSC analysis were obtained without the use of DTS in iRIGS.
The above evaluations demonstrate the effectiveness of incorporating multidimensional genomic features and strongly suggest that iRIGS is capable of nominating SCZ disease risk genes. In the next sections, we used the 104 predicted HRGs to comprehensively characterize various properties of identified (putative) SCZ risk genes to gain further biological insights into SCZ.
Tissue-specific and developmental stage-specific expression of HRGs. We collected expression data from the Genotype-Tissue Expression (GTEx) project (Methods) and observed that HRGs have more pronounced tissue specificity in the brain than LBGs (Fig. 3c) . We also observed a higher expression level of HRGs in prenatal than postnatal stages (P = 6.99 × 10
) (Fig. 3d) in the BrainSpan data 15 (Methods), while this pattern was absent for LBGs (P = 0.15) (Fig. 3d) . In addition to LBGs, we generated a set of whole-genome background genes (WBGs) by including all the human genes minus the HRGs for comparison. As expected, no difference was observed for WBGs between prenatal and postnatal stages (P = 0.27) (Supplementary Fig. 2) .
We also compared the spatiotemporal expression pattern between the 65 non-nearest HRGs and the corresponding 65 nearest non-HRG genes. We found that the non-nearest HRGs were highly expressed in prenatal stages (P = 5.83 × 10 −4 ) (Fig. 3d) , while there was no significant difference for the nearest non-HRG genes (P = 0.53) (Fig. 3d) . Interestingly, for the GTEx data, we observed that the nearest non-HRG genes were highly expressed in a majority of brain tissues, while the non-nearest HRGs were not (Supplementary Fig. 3 ).
Involvement of HRGs in biological functions implicated in SCZ.
We repeated the enrichment analysis of HRGs with the same 18 gene sets as previously used. We observed a dramatic improvement in the enrichments of SCZ-relevant gene sets compared to NRGs. Under the criterion P corrected < 0.05, NRGs were enriched in five gene sets while HRGs were enriched in ten sets, the majority of which showed remarkably enhanced ORs (Table 1) . Among the ten significantly enriched gene sets, fragile X mental retardation protein (FMRP) targets, PSD, and genes related to the presynaptic active zone (PRAZ) have been extensively implicated in SCZ due to their in-depth involvement in synaptic networks. Calcium channel and signaling (CCS) is involved in multiple functions, including synaptic plasticity modulation, and has pleiotropic effects on psychiatric diseases 5 . Targets of miR-137 have been discussed in detail for the potential etiologic mechanism of SCZ 16 . Note that some of the enriched gene sets have also been previously implicated in DNM or rare coding mutation analyses, such as FMRP targets 11 and PSD 17 , confirming the convergence between non-coding variants and coding mutations at the gene set level. Table 2 lists some of the well-established SCZ genes involved in the SCZ primary functional categories derived from the aforementioned gene sets 3, 9, [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] . Specifically, CACNA1C and CACNB2, both encoding voltage-gated calcium channel subunits, are involved in CCS and contribute to the risk for SCZ 3 . CACNA1C is differentially expressed in patients with SCZ (P = 0.03), and both CACNA1C and CACNB2 capture multiple Hi-C links in the brain Hi-C data ( Supplementary Fig. 4 ), contributing to the high PP of both genes in iRIGS. We also predicted two DNA-binding proteins, SOX2 9 and SATB2 20, 21 ( Supplementary Fig. 4 ), which have important roles in neurogenesis and have been widely implicated in SCZ. Several of our predicted HRGs are miR-137 target genes, including the aforementioned CACNA1C, and three other genes, GRIN2A, TCF4, and ZNF804A. GRIN2A, a glutamate-gated ion channel protein and a key mediator of synaptic plasticity 23, 24 , has a pdDNM and multiple regulatory connections ( Supplementary  Fig. 4) . TCF4, which encodes transcription factor 4, participates in the initiation of neuronal differentiation by regulating the intrinsic excitability of prefrontal cortical neurons 29, 30 , and knockdown of TCF4 alters the expression of genes important for developing prefrontal neocortex 29, 31 . TCF4 is also linked with numerous DREs (Supplementary Fig. 4 ) in iRIGS. The reduced expression of ZNF804A in human neurons, especially in the fetal brain, has been widely observed and hypothesized to contribute to SCZ etiology by affecting neurite growth and loss of dendritic spine density 32 . We emphasize that in addition to these well-established SCZ genes, iRIGS also nominated novel or non-canonical genes, especially genes that are distal to the index SNPs. A particular example is the rs2514218 locus, in which DRD2, the target of all effective antipsychotic drugs, is the nearest to the index SNP. At that locus, the top predicted gene is neural cell adhesion molecule 1 (NCAM1), which is distal to the index SNP, while the nearest DRD2 is ranked third among all 16 candidate genes. We took a closer look at this region to gain more insights. NCAM1 captured 55 Hi-C links in the brain Hi-C data ( Supplementary Fig. 5 ), while there was only one for DRD2. In addition, NCAM1 had 207 capture Hi-C links, many more than DRD2 (111 links). We also observed four links for NCAM1 but none for DRD2 in the FANTOM5 data. We further explored the expression patterns of NCAM1 and DRD2. In the GTEx data, DRD2 was highly expressed in basal ganglia caudate, hypothalamus, basal ganglia nucleus accumbens, basal ganglia putamen, and substantia nigra, but the expression in cortex and frontal cortex was low ( Supplementary Fig. 6 ). NCAM1 was uniformly and highly expressed in all brain tissues ( Supplementary  Fig. 6 ). In the BrainSpan data, NCAM1 showed constitutively high expression across all stages, with particularly higher expression at prenatal stages with a trajectory that peaked at the early-mid fetal stage, while DRD2 showed lower expression across all developmental stages and no obvious pattern of transition between prenatal and postnatal stages (Supplementary Fig. 7 ). The spatiotemporal expression pattern of NCAM1 is consistent with the current understanding of SCZ 36 , and all these lines of evidence highlight that NCAM1 is a promising SCZ risk gene in addition to DRD2. Note that the GTEx and BrainSpan data were not used in iRIGS; therefore, the spatiotemporal analysis of gene expression provides independent and unbiased support.
Another example is PTK2B, which is distal to the index SNP rs73229090 (the nearest gene is CLU). PTK2B encodes a kinase involved in the calcium-induced regulation of ion channels and plays an important role in regulating neuronal activity. More interestingly, PTK2B has been consistently found to interact with DAO, a potential SCZ gene implicated from non-GWAS signals 18, 19 . One pdDNM and a high number of regulatory links were observed for PTK2B ( Supplementary Fig. 8 ), promoting it as the top gene predicted by iRIGS. Collectively, these findings strongly indicate that PTK2B is a potential risk gene for SCZ.
We manually checked the remaining genes extensively, and for most of the HRGs, we found support to varying degrees for these genes to be involved in SCZ pathophysiology. We have highlighted these genes with extended supporting evidence and description in Supplementary Table 1 .
Enrichment of HRGs in gene sets leading to altered neuronal phenotypes in mouse models. As it is increasingly becoming clear that SCZ reflects perturbations of neurodevelopmental processes 9, 36 , we were interested in assessing direct phenotypic manifestations of gene knockouts in mouse models to see whether mutations in mouse genes orthologous to HRGs exhibit phenotypes highly related to the CNS 37 . Specifically, we collected 278 gene sets relevant to CNS and behavior and neurological phenotypes from the Mouse Genome Informatics (MGI) Mammalian Phenotype Ontology (MPO) database (Methods) and observed significant enrichment of HRGs in 33 gene sets after Bonferroni correction (Supple mentary Table 4 ). The enriched sets span from low-level molecular functions to broad behavioral phenotypes and brain morphologies, including "abnormal nervous system physiology" (P = 3.96 × 10 , OR = 6.86), and "abnormal behavior" (P = 3.80 × 10
, OR = 4.34). In addition, we observed that the 65 non-nearest HRGs were significantly enriched in 19 MPO gene sets (Supplementary Table 5) , while no significantly enriched gene sets were observed for the 65 nearest non-HRG genes (Supplementary Table 6 ). This result provides strong and orthogonal support for risk genes identified via iRIGS that are beyond the proximity to the GWAS index SNPs.
HRGs are likely to be potential drug targets. We were interested in whether the predicted HRGs have the potential for repositioning existing drugs for SCZ treatment. We curated a list of 2,263 confirmed druggable targets from multiple sources (Methods), and found that 28 (27%) HRGs are targets of 198 drugs that are approved by the US FDA, clinically investigational, or preclinical drugs (Supplementary Fig. 9 ; Supplementary Table 7 ). The overlap is a significant enrichment compared to LBGs (P = 3.83 × 10 −7 , OR = 3.93). We observed that the 65 non-nearest HRGs were also significantly enriched in drug targets (P = 6.30 × 10 , OR = 3.78), while the degree of enrichment of the 65 nearest non-HRG genes dramatically decreased (P = 0.03, OR = 2.13). In particular, we found that five HRGs (GRIA1, GRM3, KCNQ5, CACNA1C, and GRIN2A) are targets of nervous system drugs ( Supplementary Fig.  9 ), corresponding to a significant enrichment (P = 0.01, OR = 3.78).
One HRG, GRM3, which encodes the protein mGlu3, is of particular interest as it belongs to the G protein-coupled receptor family; these receptors are the targets of the majority of clinically used drugs 38 . While there has been support in the literature for a linkage between GRM3 and SCZ 25, 39, 40 , there have also been contrasting reports 41, 42 . The results presented here provide additional evidence to support the hypothesis that GRM3 is a SCZ risk gene. Additionally, polymorphisms in GRM3 have been shown to correlate with cognitive performance in healthy individuals 43, 44 , and cognitive impairments are an area of unmet medical need in SCZ. This suggests that our results may place mGlu3 in a particularly attractive position for the development of therapeutics for SCZ.
In addition to genes such as GRM3, which has previously been indicated to be genetically associated with SCZ, we propose that novel genes in our list may represent new candidates for the involvement in or potential treatment of SCZ. For example, TMEFF1 and TMEFF2 are family members that exhibit DE in the brain. They are composed of transmembrane proteins that include an epidermal growth factor-like domain along with two follistatin-like domains [45] [46] [47] . The extracellular domains of these proteins can be cleaved and released from the cell surface, potentially functioning as neurotrophic factors. It has been suggested that TMEFF2 may be trophic for dopamine neurons and that it can increase dendrite length in these cells 47, 48 . Cleavage of the extracellular domain of TMEFF2 is stimulated by cytokines that induce inflammation, such as interleukin-1β and tumor necrosis factor-α 49 . The fact that this protein is expressed on the cell surface suggests that it may be a candidate for drug targeting, potentially providing a completely new therapeutic strategy for SCZ and other neurological disorders.
Discussion
SCZ is a severe psychiatric disorder that is notoriously difficult to treat, which is particularly due to the poor understanding of disease etiology. Identifying risk genes at the associated loci, in our vision, is a crucial step to bridge GWAS findings and the biology of SCZ to facilitate the development of novel therapeutics. A direct benefit of this approach is drug repositioning, as risk genes shared across different diseases provide a natural lever to repurpose drugs approved for other diseases for SCZ treatment. To bridge this gap, we developed an integrative framework, iRIGS, to pinpoint risk genes from a massive pool of candidates around SCZ-associated loci by jointly modeling high-dimensional genomic features across all GWAS loci for enhanced accuracy. As a result, we provided a gene-centric view of the genetic etiology of SCZ with strong support from multiple lines of evidence. Moreover, as a proof of concept, the predicted risk genes are strongly enriched in existing drug targets, demonstrating the promise of the identified risk genes for drug repositioning for SCZ.
Our framework has a few key strengths that are worth further in-depth discussion. iRIGS jointly integrates genomic features of a set of risk genes rather than individual genes such that the weak evidence for individual risk genes is amplified by joining forces with other ones, boosting inference accuracy. A challenge for joint modeling across GWAS loci is the correlation among risk genes. In iRIGS, instead of explicitly specifying correlations among all genes, which is impractical, the correlation is derived from gene networks. The derived correlation can be viewed as a prior in a Bayesian framework for the gene-gene covariance matrix (Methods). For implementing the algorithm, we designed a Gibbs sampling strategy to achieve the following two goals: making an astronomically challenging computational problem feasible and providing a probabilistic assessment of the selected risk genes, both of which are critical. By adopting a Gibbs sampling algorithm, we transformed the high-dimensional joint modeling process into a much simpler onedimensional problem, not only solving the computational challenge but also providing a set of risk genes with probabilistic interpretations. It is of note that although the algorithm samples one gene from each of the loci at each iteration, when zero or more than one risk gene exists at a locus, the framework is still able to rank the genes by PP values without awareness of the exact number of risk genes at each locus. For loci that do not harbor risk genes for whatever reasons, this does not pose a challenge to the robustness of the algorithm, and the sampling is distributed evenly among the candidate genes such that none of them have pronounced PP values. Considering that it is almost impossible to specify a priori the number of risk genes at each locus (being either zero or larger than one), which is also very likely to vary widely across loci, the current implementation is robust even in the presence of these challenges.
Our framework is designed to take advantages of high-dimensional genomics data, and the more relevant genomic features are included the more accurate the prediction is. The PsychENCODE project 50 , for example, is actively generating various epigenomics data for psychiatric disorders, and the accuracy of risk gene predictions for SCZ will be markedly enhanced when these data are incorporated into our framework. In addition, since the genomic features of genes at individual loci are jointly modeled across all loci, the accuracy of the prediction will also be markedly improved as more loci are identified, for example, by meta-analyses of international consortia such as the Psychiatric Genomics Consortium. Moreover, the investigated genomic loci can be expanded by including sub-GWAS variants, the P values of which are less than a relatively loose threshold compared with the GWAS threshold. It is our expectation that with the expansion of both genomics data and discovered GWAS loci, the identification of risk genes will be greatly improved, advancing our understanding of the biology of SCZ for the ultimate goal of guiding the development of effective therapeutics. Note that the framework is equally applicable to other complex diseases, and especially suitable for diseases with large volumes of omics data, such as transcriptomics, functional genomics, epigenomics, and others. For example, data from single cell sequencing from various immune cell types can be used for autoimmune diseases. It is our hope that this framework is able to catalyze the translation of GWAS to biology and therapeutics for a variety of complex diseases.
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Methods
Model description of iRIGS. We collected genes in the 2 Mb region centered at a GWAS index SNP as the candidates for that particular locus. L represents the number of GWAS loci, and we denoted a vector of genes with length L, each being from one of the L GWAS loci, as (X 1 , …, X L ), and termed it a candidate risk gene set (CRGS). We denoted the corresponding genomic features for this CRGS as (D 1 , …, D L ), in which D l is a vector of genomic features collected for gene X l , and let D be the genomics data for all candidates across all GWAS loci. We used N to denote the genegene network. Now the goal was to calculate P(X 1 , …, X L |D,N) and to select a CRGS with a maximum PP, which was conditional on the collective genomic features on all genes in the L loci and on the network topology. Assuming that the genomics data of a gene only depend on the underlying gene, the following equation was applied:
The first term represents the evidence embedded in genomics data, and the second term encodes the complex correlation of risk genes in a network. Since it is impossible to explicitly specify the correlation among the genes, we implicitly derived the complex correlation from the network, with the rationale that the functional convergence of risk genes, reflected in the perspective of networks, is that disease genes are more densely connected and are therefore more highly correlated. Specifically, we approximated it with one-dimensional conditional likelihoods; that is, . . .
, where X −l is a vector of genes with the l-th gene removed. We can see that the joint PP can be approximated by one-dimensional pseudo-likelihoods as follows:
Next, the calculation was decomposed into a one-dimensional problem, evaluating one GWAS locus at a time. For each of the genes in locus l, the evidence came from the following two sources: support from the genomics data (that is,
and support from risk genes in other loci through networks (that is,
). Suppose that all of the X −l genes are risk genes, then, based on network topology, a gene at locus l that is closer to X −l is more likely to be the risk gene compared with other candidates at the same locus. We do not know, however, which genes in other loci are risk genes; therefore we were not able to pre-specify risk genes X −l . Conceptually, we employed a Gibbs sampling strategy to first sample a candidate risk gene from a given locus l based on the one-dimensional posterior, and then repeated the sampling across the remaining loci. We iterated the sampling process until the posterior distribution converged. Specifically, in each round of Gibbs sampling, we calculated the sampling frequency for each candidate gene. The frequency was compared with the last round, and if the sum of squares of frequency differences across all selected genes was smaller than a predefined threshold (1 × 10 −4 was used in this study), the sampling procedure stopped. On the basis of this sampling, we were able to assess the confidence of candidates being risk genes. Theoretically, we cast iRIGS as a Bayesian model selection problem, with each candidate in a locus being a risk gene as a model. We also defined a null (background) model X 0 to represent that the candidate is a non-risk gene. The Bayesian model selection method calculates posterior odds of X l over X 0 ; that is, = 
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